Free Trial
→ Your free book is about to disappear (From Profits Run) (Ad)tc pixel Free CLPT Stock Alerts

ClearPoint Neuro (CLPT) Financials

ClearPoint Neuro logo
$8.48 -0.01 (-0.12%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$8.49 +0.01 (+0.14%)
As of 11/13/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for ClearPoint Neuro

Annual Income Statements for ClearPoint Neuro

This table shows ClearPoint Neuro's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -26
Consolidated Net Income / (Loss)		 -8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -26
Net Income / (Loss) Continuing Operations		 -8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -26
Total Pre-Tax Income 		-8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -25
Total Operating Income		 -8.97 -7.49 -6.34 -5.25 -4.59 -6.22 -13 -16 -22 -20 -24
Total Gross Profit		 2.61 3.11 4.48 4.92 7.28 9.12 11 14 14 19 23
Total Revenue		 4.59 5.75 7.38 7.35 11 13 16 21 24 31 37
Operating Revenue		 4.59 5.75 7.38 7.35 11 13 16 21 24 31 37
Total Cost of Revenue		 1.99 2.64 2.90 2.43 3.94 3.71 5.18 7.02 10 12 14
Operating Cost of Revenue		 1.99 2.64 2.90 2.43 3.94 3.71 5.18 7.02 10 12 14
Total Operating Expenses		 12 11 11 10 12 15 24 30 36 39 47
Selling, General & Admin Expense		 8.37 4.19 4.05 4.33 4.30 5.27 8.00 9.61 12 12 16
Marketing Expense		 - 3.78 3.96 3.53 4.76 5.38 7.22 9.36 13 14 16
Research & Development Expense		 1.96 2.63 2.81 2.31 2.81 4.69 9.28 11 12 12 14
Total Other Income / (Expense), net		 0.52 -0.58 -0.83 -0.92 -0.95 -0.56 -1.04 -0.10 0.39 0.83 -1.32
Interest Expense		 1.26 1.86 0.87 0.98 0.96 1.44 0.97 0.08 -0.39 0.52 2.39
Interest & Investment Income		 0.02 - - - - - - - - 1.39 1.21
Other Income / (Expense), net		 1.77 1.28 0.04 0.06 0.01 0.88 -0.06 -0.02 - -0.04 -0.15
Income Tax Expense		 - - - - - - - - - 0.01 0.06
Basic Earnings per Share		 ($4.48) ($2.93) ($0.93) ($0.56) ($0.42) ($0.43) ($0.69) ($0.68) ($0.90) ($0.70) ($0.90)
Weighted Average Basic Shares Outstanding		 1.88M 2.75M 7.74M 10.93M 13.16M 15.85M 20.73M 24.18M 24.61M 27.03M 28.32M
Diluted Earnings per Share		 ($4.48) ($2.93) ($0.93) ($0.56) ($0.42) ($0.43) ($0.69) ($0.68) ($0.90) ($0.70) ($0.90)
Weighted Average Diluted Shares Outstanding		 1.88M 2.75M 7.74M 10.93M 13.16M 15.85M 20.73M 24.18M 24.61M 27.03M 28.32M
Weighted Average Basic & Diluted Shares Outstanding		 1.88M 2.75M 7.74M 10.93M 13.16M 15.85M 20.73M 24.61M 26.98M 27.63M 29.66M

Quarterly Income Statements for ClearPoint Neuro

This table shows ClearPoint Neuro's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.15 -4.41 -4.97 -5.39 -6.03 -5.84 -5.89 -7.79 -9.55 -11 -7.46
Consolidated Net Income / (Loss)		 -4.15 -4.41 -4.97 -5.39 -6.03 -5.84 -5.89 -7.79 -9.55 -11 -7.46
Net Income / (Loss) Continuing Operations		 -4.15 -4.41 -4.97 -5.39 -6.03 -5.84 -5.89 -7.79 -9.55 -11 -7.46
Total Pre-Tax Income 		-4.13 -4.39 -4.96 -5.39 -6.01 -5.81 -5.88 -7.78 -9.54 -11 -7.46
Total Operating Income		 -4.22 -4.72 -5.16 -5.60 -6.16 -5.68 -5.28 -7.05 -8.48 -10 -6.33
Total Gross Profit		 4.53 4.99 4.85 4.76 5.13 5.56 5.60 6.40 7.76 6.71 7.06
Total Revenue		 7.64 7.86 8.12 7.77 8.49 9.22 8.86 10 12 11 12
Operating Revenue		 7.64 7.86 8.12 7.77 8.49 9.22 8.86 10 12 11 12
Total Cost of Revenue		 3.11 2.87 3.28 3.01 3.35 3.66 3.26 4.01 4.37 4.17 5.02
Operating Cost of Revenue		 3.11 2.87 3.28 3.01 3.35 3.66 3.26 4.01 4.37 4.17 5.02
Total Operating Expenses		 8.74 9.71 10 10 11 11 11 13 16 17 13
Selling, General & Admin Expense		 2.83 2.76 3.14 3.23 4.08 3.39 3.59 5.44 5.00 5.55 3.84
Marketing Expense		 3.29 3.83 3.55 3.81 3.83 4.02 3.84 4.77 6.72 6.77 5.53
Research & Development Expense		 2.63 3.12 3.32 3.33 3.38 3.83 3.45 3.24 4.52 4.63 4.02
Total Other Income / (Expense), net		 0.09 0.33 0.20 0.22 0.16 -0.13 -0.61 -0.74 -1.07 -1.13 -1.13
Interest Expense		 -0.11 -0.33 -0.21 -0.23 0.00 0.37 0.94 1.92 1.38 1.41 1.45
Interest & Investment Income		 - - - - 0.15 0.29 0.40 - 0.35 0.29 0.29
Other Income / (Expense), net		 -0.03 0.01 -0.01 -0.01 0.00 -0.05 -0.06 -0.03 -0.04 -0.01 0.02
Income Tax Expense		 0.02 0.02 0.01 - 0.02 0.03 0.01 0.00 0.01 -0.04 -0.00
Basic Earnings per Share		 ($0.16) ($0.16) ($0.18) ($0.20) ($0.22) ($0.21) ($0.21) ($0.26) ($0.32) ($0.38) ($0.24)
Weighted Average Basic Shares Outstanding		 25.45M 27.47M 27.59M 27.03M 27.72M 28.26M 28.43M 28.32M 29.55M 30.17M 30.98M
Diluted Earnings per Share		 ($0.16) ($0.16) ($0.18) ($0.20) ($0.22) ($0.21) ($0.21) ($0.26) ($0.32) ($0.38) ($0.24)
Weighted Average Diluted Shares Outstanding		 25.45M 27.47M 27.59M 27.03M 27.72M 28.26M 28.43M 28.32M 29.55M 30.17M 30.98M
Weighted Average Basic & Diluted Shares Outstanding		 27.42M 27.60M 27.58M 27.63M 27.99M 28.43M 28.42M 29.66M 29.99M 30.50M 32.05M

Annual Cash Flow Statements for ClearPoint Neuro

This table details how cash moves in and out of ClearPoint Neuro's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -3.84 -2.09 5.97 -6.19 2.60 14 34 -26 -4.48 -3.04 27
Net Cash From Operating Activities		 -8.64 -5.82 -5.99 -4.63 -2.85 -7.81 -13 -16 -14 -8.95 -24
Net Cash From Continuing Operating Activities		 -8.64 -5.82 -5.99 -4.63 -2.85 -7.81 -13 -16 -14 -8.95 -24
Net Income / (Loss) Continuing Operations		 -8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -26
Consolidated Net Income / (Loss)		 -8.45 -8.07 -7.17 -6.16 -5.54 -6.78 -14 -16 -22 -19 -26
Depreciation Expense		 0.21 0.16 0.12 0.11 0.14 0.33 0.16 0.24 0.63 0.98 0.81
Amortization Expense		 0.47 0.42 0.43 0.56 0.84 1.11 0.63 0.30 0.76 0.97 1.51
Non-Cash Adjustments To Reconcile Net Income		 0.29 1.00 1.72 1.24 0.69 0.22 2.61 3.47 6.58 6.61 9.11
Changes in Operating Assets and Liabilities, net		 -1.16 0.67 -1.09 -0.38 1.02 -2.69 -1.68 -3.75 0.40 1.40 -9.81
Net Cash From Investing Activities		 -0.08 -0.10 -0.03 -0.06 -0.16 -0.48 -0.17 -11 8.95 -0.28 0.62
Net Cash From Continuing Investing Activities		 -0.08 -0.10 -0.03 -0.06 -0.16 -0.48 -0.17 -11 8.95 -0.28 0.62
Purchase of Property, Plant & Equipment		 -0.08 -0.10 -0.03 -0.06 -0.01 -0.04 -0.17 -0.25 -0.72 -0.28 -0.52
Divestitures		 - - - - - - - - - 0.00 1.14
Other Investing Activities, net		 - - - - - -0.44 - - - 0.00 0.00
Net Cash From Financing Activities		 4.88 3.83 12 -1.49 5.61 23 47 0.41 0.30 6.19 50
Net Cash From Continuing Financing Activities		 4.88 3.83 12 -1.49 5.61 23 47 0.41 0.30 6.19 50
Repayment of Debt		 - - 0.00 -2.00 -2.21 -2.84 - - 0.00 -10 0.00
Issuance of Debt		 - - - - 0.00 25 - - - 0.00 48
Issuance of Common Equity		 - - 12 0.00 7.82 0.00 47 0.48 0.51 17 3.82
Other Financing Activities, net		 4.88 3.83 0.00 0.51 - 0.38 -0.13 -0.07 -0.21 -0.40 -1.73
Cash Interest Paid		 0.22 0.98 0.35 0.21 0.32 1.58 0.60 0.52 0.74 0.48 0.91
Cash Income Taxes Paid		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.06 0.07

Quarterly Cash Flow Statements for ClearPoint Neuro

This table details how cash moves in and out of ClearPoint Neuro's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents		 12 -2.51 -11 -1.47 -7.72 29 -3.32 8.57 -10 -6.23 17
Net Cash From Operating Activities		 -3.84 -2.67 -1.20 -1.24 -6.17 -2.55 -3.12 -12 -7.97 -7.02 -5.11
Net Cash From Continuing Operating Activities		 -3.84 -2.67 -1.20 -1.24 -6.17 -2.55 -3.12 -12 -7.97 -7.02 -5.11
Net Income / (Loss) Continuing Operations		 -4.15 -4.41 -4.97 -5.39 -6.03 -5.84 -5.89 -7.79 -9.55 -11 -7.46
Consolidated Net Income / (Loss)		 -4.15 -4.41 -4.97 -5.39 -6.03 -5.84 -5.89 -7.79 -9.55 -11 -7.46
Depreciation Expense		 0.24 0.69 -0.20 0.24 0.10 0.40 0.07 0.25 0.09 0.15 0.10
Amortization Expense		 0.25 -0.22 0.71 0.23 0.23 0.25 0.40 0.63 1.07 1.28 1.58
Non-Cash Adjustments To Reconcile Net Income		 1.19 1.44 1.90 1.91 2.13 2.44 2.34 2.20 2.65 2.81 1.87
Changes in Operating Assets and Liabilities, net		 -1.37 -0.17 1.35 1.76 -2.61 0.20 -0.04 -7.37 -2.22 0.09 -1.20
Net Cash From Investing Activities		 0.00 - -0.01 -0.26 -0.18 -0.09 -0.20 1.09 -0.65 -0.21 -0.14
Net Cash From Continuing Investing Activities		 0.00 - -0.01 -0.26 -0.18 -0.09 -0.20 1.09 -0.65 -0.21 -0.14
Purchase of Property, Plant & Equipment		 0.00 - -0.01 -0.26 -0.18 -0.09 -0.20 -0.05 -0.65 -0.21 -0.14
Net Cash From Financing Activities		 16 0.16 -10 0.04 -1.36 32 - 20 -1.85 1.00 22
Net Cash From Continuing Financing Activities		 16 0.16 -10 0.04 -1.36 32 - 20 -1.85 1.00 22
Issuance of Common Equity		 16 0.29 - 0.12 - 3.57 - 0.25 - - 22
Other Financing Activities, net		 -0.13 -0.13 -0.06 -0.08 -1.36 -0.25 - -0.12 -1.85 0.46 0.05
Cash Interest Paid		 0.19 0.19 0.11 - 0.00 0.17 0.32 0.42 0.53 0.54 0.55
Cash Income Taxes Paid		 0.00 - - 0.06 0.00 0.01 0.06 - 0.00 0.03 0.00

Annual Balance Sheets for ClearPoint Neuro

This table presents ClearPoint Neuro's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 9.94 7.40 14 7.86 12 30 66 55 43 39 98
Total Current Assets		 8.53 6.09 13 6.65 10 25 62 51 36 33 64
Cash & Equivalents		 5.41 3.32 9.29 3.10 5.70 20 54 28 23 20 46
Accounts Receivable		 1.22 0.87 0.95 1.23 1.09 1.88 2.34 2.67 3.21 4.71 6.55
Inventories, net		 1.81 1.77 2.31 2.11 3.24 3.24 4.94 9.30 7.91 6.86 8.36
Prepaid Expenses		 0.10 0.13 0.19 0.21 0.36 0.24 0.51 1.72 1.91 1.68 2.77
Plant, Property, & Equipment, net		 0.44 0.33 0.27 0.38 0.45 0.32 0.54 0.81 1.39 2.01 2.62
Total Noncurrent Assets		 0.96 0.99 0.88 0.82 1.10 3.74 3.15 3.50 5.10 3.82 32
Goodwill		 - - - - - - - - - 0.00 7.47
Intangible Assets		 - - - - - - - - 1.04 0.00 14
Other Noncurrent Operating Assets		 0.96 0.99 0.88 0.82 1.10 3.74 3.15 3.50 4.06 3.82 10
Total Liabilities & Shareholders' Equity		 9.94 7.40 14 7.86 12 30 66 55 43 39 98
Total Liabilities		 12 8.16 8.07 6.35 7.34 27 17 19 21 14 70
Total Current Liabilities		 7.65 3.02 4.40 1.87 3.83 3.20 4.75 6.79 7.43 10 11
Accounts Payable		 0.70 1.55 0.76 0.50 0.97 0.30 0.43 0.27 0.39 1.34 1.26
Accrued Expenses		 1.40 0.45 0.48 0.39 0.33 0.35 0.54 2.07 1.05 1.45 2.79
Current Deferred Revenue		 0.12 0.22 0.26 0.21 1.02 0.56 0.68 1.07 2.61 2.12 1.67
Current Employee Benefit Liabilities		 0.56 0.67 0.81 0.76 1.41 1.60 2.60 2.82 2.95 4.89 4.36
Other Current Liabilities		 0.66 0.13 0.10 0.00 0.11 0.39 0.51 0.56 0.42 0.56 0.69
Total Noncurrent Liabilities		 0.54 5.14 3.67 4.48 3.51 24 12 12 14 3.45 58
Long-Term Debt		 0.00 4.49 2.92 3.48 2.07 21 9.84 9.89 9.95 0.00 49
Noncurrent Deferred Revenue		 - - - 0.14 0.20 0.22 0.26 0.39 0.54 0.44 0.58
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 0.00 0.35
Other Noncurrent Operating Liabilities		 0.54 0.65 0.75 0.86 1.24 2.45 1.94 1.53 3.57 3.01 8.46
Commitments & Contingencies		 - 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.98 -0.76 5.83 1.51 4.59 2.38 49 37 21 25 28
Total Preferred & Common Equity		 -1.98 -0.76 5.83 1.51 4.59 2.38 49 37 21 25 28
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -1.98 -0.76 5.83 1.51 4.59 2.38 49 37 21 25 28
Common Stock		 84 93 107 109 117 122 183 187 194 217 245
Retained Earnings		 -86 -94 -101 -107 -113 -120 -134 -150 -172 -191 -217

Quarterly Balance Sheets for ClearPoint Neuro

This table presents ClearPoint Neuro's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets		 48 44 54 53 40 30 63 60 93 87 113
Total Current Assets		 41 37 48 47 34 24 54 51 55 49 67
Cash & Equivalents		 26 24 35 33 22 12 42 38 36 29 46
Accounts Receivable		 2.80 2.42 2.51 3.48 3.88 3.65 4.26 4.00 8.66 8.40 8.02
Inventories, net		 9.20 8.99 7.96 8.03 7.06 6.58 6.29 6.58 8.57 8.81 9.77
Prepaid Expenses		 2.24 1.56 1.75 2.21 1.82 1.59 1.90 2.53 2.05 2.36 2.74
Plant, Property, & Equipment, net		 1.36 1.36 1.35 1.55 1.70 2.18 2.02 2.11 2.91 2.99 3.12
Total Noncurrent Assets		 5.57 5.17 4.72 4.47 4.17 3.67 6.86 6.91 36 35 43
Goodwill		 - - - - - - - - 7.47 7.47 7.47
Intangible Assets		 - 0.97 0.89 0.76 0.61 0.46 - - 13 13 12
Other Noncurrent Operating Assets		 5.57 4.20 3.83 3.72 3.56 3.22 6.86 6.91 15 14 23
Total Liabilities & Shareholders' Equity		 48 44 54 53 40 30 63 60 93 87 113
Total Liabilities		 20 20 19 20 11 10 43 44 75 76 85
Total Current Liabilities		 6.20 5.59 15 17 7.55 6.87 7.40 8.05 9.48 10 9.87
Accounts Payable		 1.27 0.79 0.84 0.82 0.96 1.22 1.53 0.72 2.33 2.15 1.06
Accrued Expenses		 1.37 0.95 0.99 1.30 1.18 1.51 1.21 1.75 2.13 1.98 2.50
Current Deferred Revenue		 0.72 1.18 1.23 1.08 1.25 1.62 0.00 1.72 1.81 1.84 1.55
Current Employee Benefit Liabilities		 2.34 2.29 1.63 3.00 3.64 1.94 2.95 3.52 2.98 4.14 4.56
Other Current Liabilities		 0.49 0.38 0.50 0.52 0.54 0.58 1.71 0.35 0.23 0.19 0.20
Total Noncurrent Liabilities		 14 14 3.90 3.75 3.64 3.22 36 36 65 66 76
Long-Term Debt		 9.92 9.94 0.00 0.00 0.00 0.00 29 29 50 50 51
Noncurrent Deferred Revenue		 0.25 0.52 0.46 0.45 0.48 0.36 0.00 0.77 0.61 0.51 0.43
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - 0.35 0.32 0.31
Other Noncurrent Operating Liabilities		 3.86 3.70 3.44 3.30 3.16 2.86 6.88 6.46 14 15 24
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 27 24 35 32 29 20 20 16 19 11 27
Total Preferred & Common Equity		 27 24 35 32 29 20 20 16 19 11 27
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 27 24 35 32 29 20 20 16 19 11 27
Common Stock		 190 192 211 213 215 217 223 225 245 249 273
Retained Earnings		 -163 -168 -177 -181 -186 -197 -203 -209 -226 -238 -245

Annual Metrics And Ratios for ClearPoint Neuro

This table displays calculated financial ratios and metrics derived from ClearPoint Neuro's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 74,971,026.00 3,610,524.00 10,401,115.00 11,022,372.00 15,205,867.00 16,869,528.00 23,639,616.00 - - - 28,423,308.00
DEI Adjusted Shares Outstanding		 74,971,026.00 3,610,524.00 10,401,115.00 11,022,372.00 15,205,867.00 16,869,528.00 23,639,616.00 - - - 28,423,308.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.11 -2.24 -0.69 -0.56 -0.36 -0.40 -0.61 - - - -0.90
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 27.46% 25.15% 28.35% -0.36% 52.54% 14.37% 27.05% 26.09% 16.56% 31.04% 17.78%
EBITDA Growth		 -125.84% 13.71% -2.22% 21.56% 20.09% -8.13% -224.40% -25.00% -33.23% 15.32% -23.40%
EBIT Growth		 -100.35% 13.84% -1.41% 17.65% 11.55% -16.42% -151.72% -21.71% -37.25% 11.85% -22.94%
NOPAT Growth		 -68.67% 16.55% 15.40% 17.17% 12.46% -35.39% -115.02% -22.12% -37.44% 12.03% -22.45%
Net Income Growth		 -86.73% 4.49% 11.18% 14.01% 10.12% -22.42% -112.47% -14.05% -34.40% 14.37% -35.03%
EPS Growth		 -5,500.00% 34.60% 68.26% 39.78% 25.00% -2.38% -60.47% 1.45% -32.35% 22.22% -28.57%
Operating Cash Flow Growth		 -19.14% 32.62% -2.96% 22.73% 38.45% -173.93% -62.64% -27.33% 15.14% 34.77% -167.32%
Free Cash Flow Firm Growth		 -112.43% 39.89% -7.19% 24.95% 44.28% -203.68% -48.51% -57.05% 11.13% 22.76% -285.04%
Invested Capital Growth		 133.69% -24.63% 246.98% 29.75% -49.06% 269.47% 26.93% 105.74% -14.09% -33.79% 489.86%
Revenue Q/Q Growth		 13.65% 2.20% 0.60% 8.84% 9.08% 4.10% 3.60% 4.54% 7.33% 3.16% 7.69%
EBITDA Q/Q Growth		 11.33% -12.99% -6.76% 16.61% -10.57% 2.61% -27.68% -4.45% 0.75% -5.35% -4.86%
EBIT Q/Q Growth		 10.28% -10.55% -6.43% 14.31% -10.53% 0.73% -24.08% -3.21% -1.07% -4.98% -6.22%
NOPAT Q/Q Growth		 12.30% -5.21% -0.67% 14.00% -10.58% -15.74% -14.74% -3.07% -1.07% -4.76% -6.14%
Net Income Q/Q Growth		 7.82% -6.36% -5.92% 12.29% -8.37% 0.93% -21.68% -1.46% -1.07% -4.23% -10.37%
EPS Q/Q Growth		 -134.56% 45.44% 18.42% -21.74% 2.33% 99.52% -100.77% 4.23% 0.00% -2.94% -7.14%
Operating Cash Flow Q/Q Growth		 7.26% 3.41% -11.83% 20.08% 3.91% -32.95% -9.97% 2.92% 12.14% -0.83% -82.80%
Free Cash Flow Firm Q/Q Growth		 12.46% 1.70% -11.27% 23.03% -300.21% 3.71% -14.50% 0.60% 9.63% -1.74% -178.58%
Invested Capital Q/Q Growth		 72.88% -21.14% 39.44% -10.36% 523.83% 10.23% 10.63% -0.05% -17.60% -28.85% 354.70%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 56.74% 54.03% 60.72% 66.91% 64.86% 71.09% 68.24% 65.84% 56.83% 60.92% 61.38%
EBITDA Margin		 -141.92% -97.86% -77.94% -61.35% -32.14% -30.38% -77.58% -76.91% -87.91% -56.81% -59.48%
Operating Margin		 -195.34% -130.25% -85.86% -71.37% -40.96% -48.48% -82.05% -79.47% -93.70% -62.91% -65.36%
EBIT Margin		 -156.79% -107.95% -85.30% -70.49% -40.88% -41.61% -82.44% -79.58% -93.70% -63.03% -65.75%
Profit (Net Income) Margin		 -183.91% -140.36% -97.12% -83.82% -49.39% -52.86% -88.41% -79.97% -92.21% -60.25% -69.08%
Tax Burden Percent		 100.00% 100.00% 100.00% 99.99% 100.00% 100.00% 100.00% 100.00% 100.13% 100.00% 100.22%
Interest Burden Percent		 117.30% 130.02% 113.87% 118.91% 120.83% 127.05% 107.24% 100.50% 98.28% 95.59% 104.83%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -1,073.09% -472.59% -219.47% -225.39% -192.61% -231.90% -165.60% -181.93% -208.37% -92.79%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -1,225.35% -301.59% -94.73% -82.08% 6.24% -208.47% -151.68% -150.66% -177.78% 8.98%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 1,662.73% 190.00% 51.52% 43.66% -2.19% 175.57% 127.24% 105.84% 127.13% -2.85%
Return on Equity (ROE)		 811.85% 589.64% -282.59% -167.95% -181.73% -194.80% -56.33% -38.37% -76.09% -81.24% -95.64%
Cash Return on Invested Capital (CROIC)		 -1,524.42% -1,045.00% -583.10% -245.37% -160.38% -307.41% -255.63% -234.77% -166.77% -167.71% -234.81%
Operating Return on Assets (OROA)		 -61.77% -71.60% -59.11% -47.65% -46.35% -25.76% -28.26% -27.02% -45.74% -48.35% -35.51%
Return on Assets (ROA)		 -72.46% -93.09% -67.30% -56.66% -56.01% -32.73% -30.31% -27.15% -45.01% -46.22% -37.30%
Return on Common Equity (ROCE)		 811.85% 589.64% -282.59% -167.95% -181.73% -194.80% -56.33% -38.37% -76.09% -81.24% -95.64%
Return on Equity Simple (ROE_SIMPLE)		 426.48% 1,067.35% -122.97% -407.91% -120.80% -285.32% -29.54% -44.56% -104.33% -74.50% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.28 -5.24 -4.44 -3.67 -3.22 -4.35 -9.36 -11 -16 -14 -17
NOPAT Margin		 -136.74% -91.18% -60.10% -49.96% -28.67% -33.94% -57.44% -55.63% -65.59% -44.03% -45.75%
Net Nonoperating Expense Percent (NNEP)		 440.12% 152.27% -170.99% -124.74% -143.31% -198.85% -23.43% -13.92% -31.27% -30.59% -101.77%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -50.49% -54.44% -21.94%
Cost of Revenue to Revenue		 43.26% 45.97% 39.28% 33.09% 35.14% 28.91% 31.76% 34.16% 43.17% 39.08% 38.62%
SG&A Expenses to Revenue		 182.20% 72.88% 54.83% 58.83% 38.36% 41.08% 49.08% 46.77% 49.08% 38.22% 44.62%
R&D to Revenue		 42.60% 45.71% 38.13% 31.42% 25.05% 36.53% 56.94% 53.01% 48.88% 39.48% 37.59%
Operating Expenses to Revenue		 252.07% 184.29% 146.58% 138.28% 105.81% 119.57% 150.30% 145.31% 150.53% 123.82% 126.74%
Earnings before Interest and Taxes (EBIT)		 -7.20 -6.21 -6.29 -5.18 -4.59 -5.34 -13 -16 -22 -20 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.52 -5.63 -5.75 -4.51 -3.61 -3.90 -13 -16 -21 -18 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.05 13.57 15.92 112.77 5.44 5.64 7.90 16.71 13.88
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.05 13.57 15.92 112.77 5.44 5.64 8.30 17.03 58.68
Price to Revenue (P/Rev)		 18.77 0.72 1.62 2.79 6.51 20.89 16.27 10.12 6.98 13.52 10.52
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 152.63 12.69 5.21 11.05 72.03 75.67 48.93 19.41 19.29 76.47 12.57
Enterprise Value to Revenue (EV/Rev)		 18.51 0.93 1.03 2.84 6.18 20.99 13.56 8.78 6.43 12.88 10.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -2.13 -5.94 0.84 2.30 0.45 8.95 0.20 0.27 0.47 0.00 1.75
Long-Term Debt to Equity		 0.00 -5.94 0.50 2.30 0.45 8.95 0.20 0.27 0.47 0.00 1.75
Financial Leverage		 -0.47 -1.36 -0.63 -0.54 -0.53 -0.35 -0.84 -0.84 -0.70 -0.72 -0.32
Leverage Ratio		 -11.20 -6.33 4.20 2.96 3.24 5.95 1.86 1.41 1.69 1.76 2.56
Compound Leverage Factor		 -13.14 -8.24 4.78 3.52 3.92 7.56 1.99 1.42 1.66 1.68 2.69
Debt to Total Capital		 188.31% 120.24% 45.76% 69.73% 31.13% 89.95% 16.78% 21.15% 31.97% 0.00% 63.66%
Short-Term Debt to Total Capital		 188.31% 0.00% 18.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 120.24% 27.15% 69.73% 31.13% 89.95% 16.78% 21.15% 31.97% 0.00% 63.66%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -88.31% -20.24% 54.24% 30.27% 68.87% 10.05% 83.22% 78.85% 68.03% 100.00% 36.34%
Debt to EBITDA		 -0.65 -0.80 -0.86 -0.77 -0.58 -5.46 -0.78 -0.63 -0.47 0.00 -2.23
Net Debt to EBITDA		 0.18 -0.21 0.76 -0.08 1.01 -0.30 3.50 1.75 0.63 0.00 -0.14
Long-Term Debt to EBITDA		 0.00 -0.80 -0.51 -0.77 -0.58 -5.46 -0.78 -0.63 -0.47 0.00 -2.23
Debt to NOPAT		 -0.67 -0.86 -1.11 -0.95 -0.64 -4.89 -1.05 -0.87 -0.63 0.00 -2.90
Net Debt to NOPAT		 0.19 -0.22 0.99 -0.10 1.13 -0.27 4.73 2.41 0.84 0.00 -0.19
Long-Term Debt to NOPAT		 0.00 -0.86 -0.66 -0.95 -0.64 -4.89 -1.05 -0.87 -0.63 0.00 -2.90
Altman Z-Score		 -9.56 -18.94 -9.53 -17.67 -6.94 1.00 7.23 3.27 -1.36 11.45 0.45
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.11 2.02 2.90 3.56 2.71 7.96 13.02 7.54 4.87 3.22 5.91
Quick Ratio		 0.87 1.39 2.33 2.32 1.77 6.87 11.88 5.92 3.55 2.40 4.87
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.49 -5.10 -5.47 -4.11 -2.29 -6.95 -10 -16 -14 -11 -43
Operating Cash Flow to CapEx		 -11,234.91% -5,762.30% -22,400.24% -7,293.42% -28,500.00% -19,041.46% -7,557.74% -6,390.12% -1,913.53% -3,254.55% -4,583.33%
Free Cash Flow to Firm to Interest Expense		 -6.73 -2.74 -6.27 -4.19 -2.40 -4.81 -10.61 -200.09 0.00 0.00 -17.92
Operating Cash Flow to Interest Expense		 -6.84 -3.12 -6.86 -4.72 -2.98 -5.41 -13.05 -199.59 0.00 0.00 -10.02
Operating Cash Flow Less CapEx to Interest Expense		 -6.90 -3.18 -6.90 -4.79 -2.99 -5.43 -13.22 -202.72 0.00 0.00 -10.24
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.39 0.66 0.69 0.68 1.13 0.62 0.34 0.34 0.49 0.77 0.54
Accounts Receivable Turnover		 5.45 5.52 8.13 6.74 9.65 8.64 7.73 8.22 8.15 7.92 6.57
Inventory Turnover		 1.05 1.48 1.42 1.10 1.47 1.15 1.27 0.99 1.20 1.66 1.88
Fixed Asset Turnover		 9.95 14.96 24.77 22.79 27.20 33.50 37.99 30.56 21.83 18.50 15.98
Accounts Payable Turnover		 2.35 2.35 2.51 3.86 5.37 5.86 14.24 20.09 31.10 14.16 11.00
Days Sales Outstanding (DSO)		 67.01 66.15 44.89 54.19 37.81 42.26 47.23 44.42 44.77 46.07 55.59
Days Inventory Outstanding (DIO)		 346.42 246.97 257.03 331.55 247.50 318.75 288.28 370.23 303.80 219.78 194.55
Days Payable Outstanding (DPO)		 155.62 155.01 145.20 94.54 67.91 62.29 25.63 18.17 11.74 25.78 33.18
Cash Conversion Cycle (CCC)		 257.81 158.10 156.72 291.20 217.40 298.72 309.87 396.47 336.83 240.07 216.97
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.56 0.42 1.46 1.89 0.96 3.56 4.52 9.29 7.98 5.29 31
Invested Capital Turnover		 -8.38 11.77 7.86 4.39 7.86 5.68 4.04 2.98 2.77 4.73 2.03
Increase / (Decrease) in Invested Capital		 2.21 -0.14 1.04 0.43 -0.93 2.60 0.96 4.78 -1.31 -2.70 26
Enterprise Value (EV)		 85 5.33 7.59 21 69 269 221 180 154 404 392
Market Capitalization		 86 4.15 12 21 73 268 265 208 167 424 389
Book Value per Share		 ($0.03) ($0.21) $0.56 $0.14 $0.30 $0.14 $2.06 $1.50 $0.86 $0.92 $0.99
Tangible Book Value per Share		 ($0.03) ($0.21) $0.56 $0.14 $0.30 $0.14 $2.06 $1.50 $0.82 $0.90 $0.23
Total Capital		 2.24 3.74 11 4.99 6.66 24 59 47 31 25 77
Total Debt		 4.22 4.49 4.92 3.48 2.07 21 9.84 9.89 9.95 0.00 49
Total Long-Term Debt		 0.00 4.49 2.92 3.48 2.07 21 9.84 9.89 9.95 0.00 49
Net Debt		 -1.18 1.18 -4.37 0.38 -3.62 1.18 -44 -28 -13 -20 3.15
Capital Expenditures (CapEx)		 0.08 0.10 0.03 0.06 0.01 0.04 0.17 0.25 0.72 0.28 0.52
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.31 -0.25 1.06 1.69 0.86 2.16 3.03 6.90 5.60 2.91 6.91
Debt-free Net Working Capital (DFNWC)		 5.10 3.07 10 4.79 6.55 22 57 44 29 23 53
Net Working Capital (NWC)		 0.88 3.07 8.35 4.79 6.55 22 57 44 29 23 53
Net Nonoperating Expense (NNE)		 2.17 2.83 2.73 2.49 2.32 2.43 5.05 5.00 6.38 5.09 8.63
Net Nonoperating Obligations (NNO)		 2.54 1.18 -4.37 0.38 -3.62 1.18 -44 -28 -13 -20 3.15
Total Depreciation and Amortization (D&A)		 0.68 0.58 0.54 0.67 0.98 1.44 0.79 0.55 1.39 1.95 2.32
Debt-free, Cash-free Net Working Capital to Revenue		 -6.65% -4.32% 14.34% 22.93% 7.62% 16.86% 18.59% 33.59% 23.39% 9.26% 18.70%
Debt-free Net Working Capital to Revenue		 111.08% 53.35% 140.23% 65.10% 58.40% 173.53% 350.57% 216.01% 119.98% 73.30% 142.91%
Net Working Capital to Revenue		 19.12% 53.35% 113.13% 65.10% 58.40% 173.53% 350.57% 216.01% 119.98% 73.30% 142.91%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.11) ($2.93) ($0.93) ($0.56) ($0.42) ($0.43) ($0.69) ($0.68) ($0.90) ($0.70) ($0.90)
Adjusted Weighted Average Basic Shares Outstanding		 91.65M 3.62M 10.69M 11.05M 15.49M 20.67M 23.69M 24.18M 24.61M 27.03M 28.32M
Adjusted Diluted Earnings per Share		 ($0.11) ($2.93) ($0.93) ($0.56) ($0.42) ($0.43) ($0.69) ($0.68) ($0.90) ($0.70) ($0.90)
Adjusted Weighted Average Diluted Shares Outstanding		 91.65M 3.62M 10.69M 11.05M 15.49M 20.67M 23.69M 24.18M 24.61M 27.03M 28.32M
Adjusted Basic & Diluted Earnings per Share		 ($0.11) ($2.93) ($0.93) ($0.56) ($0.42) ($0.43) ($0.69) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 75.39M 2.75M 7.74M 10.93M 13.16M 15.85M 20.73M 24.61M 26.98M 27.63M 29.66M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.41 -5.24 -4.44 -3.67 -3.22 -4.35 -9.36 -11 -16 -14 -17
Normalized NOPAT Margin		 -117.65% -91.18% -60.10% -49.96% -28.67% -33.94% -57.44% -55.63% -65.59% -44.03% -45.75%
Pre Tax Income Margin		 -183.91% -140.36% -97.12% -83.82% -49.39% -52.86% -88.41% -79.97% -92.09% -60.25% -68.93%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -5.71 -3.33 -7.21 -5.29 -4.80 -3.70 -13.81 -201.90 0.00 0.00 -10.18
NOPAT to Interest Expense		 -4.98 -2.81 -5.08 -3.75 -3.37 -3.02 -9.62 -141.14 0.00 0.00 -7.08
EBIT Less CapEx to Interest Expense		 -5.77 -3.39 -7.24 -5.35 -4.81 -3.73 -13.98 -205.02 0.00 0.00 -10.40
NOPAT Less CapEx to Interest Expense		 -5.04 -2.87 -5.11 -3.81 -3.38 -3.04 -9.79 -144.26 0.00 0.00 -7.30
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for ClearPoint Neuro

This table displays calculated financial ratios and metrics derived from ClearPoint Neuro's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding		 - - - - 27,632,332.00 27,989,194.00 28,427,417.00 28,423,308.00 29,663,875.00 29,989,563.00 30,504,227.00
DEI Adjusted Shares Outstanding		 - - - - 27,632,332.00 27,989,194.00 28,427,417.00 28,423,308.00 29,663,875.00 29,989,563.00 30,504,227.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - -0.22 -0.21 -0.21 -0.27 -0.32 -0.38 -0.24
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 40.60% 32.07% 40.96% 14.11% 11.07% 17.27% 9.10% 33.96% 42.93% 18.07% 36.27%
EBITDA Growth		 31.58% 37.74% -4.62% -20.48% -55.21% -19.87% -4.79% -19.95% -26.32% -73.55% 5.07%
EBIT Growth		 25.62% 33.63% -5.84% -19.25% -45.19% -21.47% -3.31% -25.43% -38.22% -78.84% -18.16%
NOPAT Growth		 25.93% 33.54% -5.62% -19.08% -46.18% -20.24% -2.29% -25.00% -37.56% -80.35% -20.02%
Net Income Growth		 26.08% 37.49% -3.43% -16.61% -45.34% -32.42% -18.44% -44.56% -58.51% -94.23% -26.63%
EPS Growth		 30.43% 44.83% 10.00% -11.11% -37.50% -31.25% -16.67% -30.00% -45.45% -80.95% -14.29%
Operating Cash Flow Growth		 32.39% 47.43% 33.24% -6.33% -60.73% 4.35% -160.30% -871.84% -29.08% -174.88% -63.79%
Free Cash Flow Firm Growth		 84.09% 79.35% 64.35% 38.25% -95.03% -3.00% -130.93% -2,369.20% -1,048.42% -1,708.13% -845.13%
Invested Capital Growth		 -14.48% -14.73% -23.32% -33.79% -17.35% -23.95% -7.70% 489.86% 332.79% 349.06% 365.62%
Revenue Q/Q Growth		 12.17% 2.87% 3.36% -4.32% 9.19% 8.60% -3.84% 17.48% 16.50% -10.29% 10.98%
EBITDA Q/Q Growth		 11.78% -12.98% -9.61% -10.18% -12.60% 12.70% 4.13% -27.28% -18.58% -19.94% 47.56%
EBIT Q/Q Growth		 9.62% -11.21% -9.48% -8.28% -9.12% 6.93% 6.84% -32.57% -20.26% -20.42% 38.45%
NOPAT Q/Q Growth		 10.09% -12.01% -9.14% -8.35% -9.35% 7.84% 7.11% -33.53% -20.34% -20.83% 38.19%
Net Income Q/Q Growth		 10.24% -6.32% -12.84% -8.28% -11.88% 3.14% -0.93% -32.17% -22.68% -18.69% 34.20%
EPS Q/Q Growth		 11.11% 0.00% -12.50% -11.11% -10.00% 4.55% 0.00% -23.81% -23.08% -18.75% 36.84%
Operating Cash Flow Q/Q Growth		 -228.49% 30.52% 55.06% -3.67% -396.54% 58.65% -22.30% -287.06% 34.05% 11.95% 27.13%
Free Cash Flow Firm Q/Q Growth		 29.24% -22.18% 20.68% 9.96% -117.84% 35.38% -77.64% -887.46% -1.32% -1.74% 7.14%
Invested Capital Q/Q Growth		 15.20% 0.77% -19.84% -28.85% 43.80% -7.28% -2.71% 354.70% 5.51% -3.79% 0.88%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 59.24% 63.48% 59.68% 61.28% 60.48% 60.29% 63.20% 61.52% 63.95% 61.67% 58.46%
EBITDA Margin		 -49.33% -54.17% -57.45% -66.16% -68.65% -55.18% -55.02% -59.61% -60.67% -81.11% -38.33%
Operating Margin		 -55.39% -60.31% -63.68% -72.11% -72.63% -61.64% -59.54% -67.68% -69.90% -94.15% -52.44%
EBIT Margin		 -55.73% -60.24% -63.81% -72.22% -72.59% -62.20% -60.26% -68.00% -70.19% -94.22% -52.26%
Profit (Net Income) Margin		 -54.27% -56.10% -61.24% -69.31% -71.02% -63.34% -66.48% -74.79% -78.76% -104.20% -61.78%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.30% 100.43% 100.14% 100.05% 100.08% 99.67% 99.95%
Interest Burden Percent		 97.39% 93.11% 95.97% 95.97% 97.55% 101.40% 110.17% 109.93% 112.11% 110.96% 118.29%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -101.70% -117.71% -158.50% -238.87% -195.18% -177.70% -200.35% -96.08% -98.16% -144.04% -86.13%
ROIC Less NNEP Spread (ROIC-NNEP)		 -96.68% -112.18% -150.98% -230.08% -186.11% -167.24% -185.99% -62.39% -532.94% -245.99% 52.69%
Return on Net Nonoperating Assets (RNNOA)		 67.97% 74.25% 102.31% 164.53% 128.83% 114.65% 126.79% 19.80% -22.84% -65.88% -5.33%
Return on Equity (ROE)		 -33.73% -43.47% -56.19% -74.35% -66.34% -63.06% -73.57% -76.27% -121.00% -209.91% -91.45%
Cash Return on Invested Capital (CROIC)		 -131.53% -113.25% -127.78% -167.71% -161.74% -167.17% -215.13% -234.81% -216.47% -239.47% -245.17%
Operating Return on Assets (OROA)		 -28.07% -33.75% -46.22% -55.39% -55.91% -36.20% -41.15% -36.72% -46.17% -53.25% -27.47%
Return on Assets (ROA)		 -27.34% -31.42% -44.35% -53.16% -54.70% -36.86% -45.40% -40.39% -51.81% -58.89% -32.48%
Return on Common Equity (ROCE)		 -33.73% -43.47% -56.19% -74.35% -66.34% -63.06% -73.57% -76.27% -121.00% -209.91% -91.45%
Return on Equity Simple (ROE_SIMPLE)		 -59.64% -55.96% -62.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.96 -3.32 -3.62 -3.92 -4.31 -3.98 -3.69 -4.93 -5.93 -7.17 -4.43
NOPAT Margin		 -38.77% -42.22% -44.58% -50.48% -50.84% -43.15% -41.68% -47.37% -48.93% -65.91% -36.71%
Net Nonoperating Expense Percent (NNEP)		 -5.02% -5.54% -7.52% -8.79% -9.06% -10.47% -14.37% -33.68% 434.78% 101.95% -138.82%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -15.45% -21.58% -8.18% -8.19% -6.40% -8.67% -11.75% -5.67%
Cost of Revenue to Revenue		 40.76% 36.52% 40.32% 38.72% 39.52% 39.71% 36.80% 38.48% 36.05% 38.33% 41.54%
SG&A Expenses to Revenue		 37.19% 35.29% 38.85% 41.55% 48.11% 36.77% 40.47% 52.28% 41.20% 51.05% 31.81%
R&D to Revenue		 34.36% 39.70% 40.82% 42.88% 39.82% 41.55% 38.96% 31.10% 37.29% 42.57% 33.28%
Operating Expenses to Revenue		 114.62% 123.78% 123.36% 133.39% 133.12% 121.93% 122.74% 129.19% 133.86% 155.83% 110.90%
Earnings before Interest and Taxes (EBIT)		 -4.26 -4.73 -5.18 -5.61 -6.16 -5.73 -5.34 -7.08 -8.51 -10 -6.31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.77 -4.26 -4.67 -5.14 -5.83 -5.09 -4.88 -6.21 -7.36 -8.83 -4.63
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.30 4.60 10.67 16.71 16.44 16.93 39.02 13.88 14.33 49.65 13.66
Price to Tangible Book Value (P/TBV)		 5.44 4.71 10.90 17.03 16.82 16.93 39.02 58.68 0.00 0.00 50.45
Price to Revenue (P/Rev)		 7.01 5.27 10.17 13.52 10.19 9.95 18.04 10.52 6.65 12.65 8.19
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 17.19 13.48 38.74 76.47 41.60 45.62 89.03 12.57 8.63 17.57 11.81
Enterprise Value to Revenue (EV/Rev)		 6.04 4.45 9.46 12.88 9.81 9.57 17.78 10.60 6.99 13.15 8.29
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.29 0.31 0.00 0.00 0.00 1.46 1.84 1.75 2.63 4.66 1.86
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 1.46 1.84 1.75 2.63 4.66 1.86
Financial Leverage		 -0.70 -0.66 -0.68 -0.72 -0.69 -0.69 -0.68 -0.32 0.04 0.27 -0.10
Leverage Ratio		 1.55 1.68 1.58 1.76 1.53 2.23 2.24 2.56 3.18 4.90 4.01
Compound Leverage Factor		 1.51 1.57 1.52 1.69 1.50 2.26 2.47 2.82 3.57 5.44 4.75
Debt to Total Capital		 22.37% 23.70% 0.00% 0.00% 0.00% 59.37% 64.78% 63.66% 72.49% 82.34% 65.09%
Short-Term Debt to Total Capital		 22.37% 23.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 59.37% 64.78% 63.66% 72.49% 82.34% 65.09%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 77.63% 76.30% 100.00% 100.00% 100.00% 40.63% 35.22% 36.34% 27.51% 17.66% 34.91%
Debt to EBITDA		 -0.52 -0.60 0.00 0.00 0.00 -1.39 -1.39 -2.23 -2.11 -1.84 -1.88
Net Debt to EBITDA		 1.31 1.36 0.00 0.00 0.00 0.61 0.43 -0.14 -0.60 -0.77 -0.17
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -1.39 -1.39 -2.23 -2.11 -1.84 -1.88
Debt to NOPAT		 -0.68 -0.77 0.00 0.00 0.00 -1.82 -1.83 -2.90 -2.68 -2.31 -2.26
Net Debt to NOPAT		 1.73 1.76 0.00 0.00 0.00 0.80 0.57 -0.19 -0.76 -0.96 -0.21
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -1.82 -1.83 -2.90 -2.68 -2.31 -2.26
Altman Z-Score		 2.12 0.44 11.24 12.64 11.45 1.25 4.64 1.03 -0.50 1.02 0.39
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.14 2.79 4.54 3.22 3.53 7.30 6.37 5.91 5.79 4.74 6.76
Quick Ratio		 2.50 2.18 3.37 2.40 2.34 6.19 5.24 4.87 4.67 3.66 5.49
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.40 -1.72 -1.36 -1.23 -2.72 -1.76 -3.12 -31 -31 -32 -29
Operating Cash Flow to CapEx		 0.00% 0.00% -9,991.67% -472.62% -3,372.68% -2,804.40% -1,568.34% -24,653.06% -1,235.19% -3,278.04% -3,731.39%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -21.96 -5.75 -16.09 -22.60 -22.48 -20.40
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -31.90 -5.75 -6.30 -5.76 -4.96 -3.54
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -33.04 -6.11 -6.33 -6.23 -5.12 -3.63
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.50 0.56 0.72 0.77 0.77 0.58 0.68 0.54 0.66 0.57 0.53
Accounts Receivable Turnover		 10.08 8.95 9.66 7.92 10.46 8.69 8.72 6.57 6.60 6.68 7.57
Inventory Turnover		 1.26 1.31 1.50 1.66 1.72 1.86 1.95 1.88 2.02 2.09 2.15
Fixed Asset Turnover		 22.79 19.32 19.95 18.50 18.26 18.85 18.03 15.98 15.94 16.89 17.38
Accounts Payable Turnover		 10.22 10.76 13.83 14.16 12.14 11.30 15.83 11.00 8.63 8.58 19.70
Days Sales Outstanding (DSO)		 36.20 40.79 37.78 46.07 34.89 42.02 41.86 55.59 55.33 54.63 48.21
Days Inventory Outstanding (DIO)		 288.90 279.09 242.90 219.78 212.19 196.61 187.45 194.55 180.79 174.38 169.94
Days Payable Outstanding (DPO)		 35.71 33.93 26.40 25.78 30.06 32.30 23.06 33.18 42.30 42.53 18.53
Cash Conversion Cycle (CCC)		 289.40 285.96 254.28 240.07 217.02 206.33 206.25 216.97 193.82 186.48 199.62
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 9.20 9.27 7.43 5.29 7.60 7.05 6.86 31 33 32 32
Invested Capital Turnover		 2.62 2.79 3.56 4.73 3.84 4.12 4.81 2.03 2.01 2.19 2.35
Increase / (Decrease) in Invested Capital		 -1.56 -1.60 -2.26 -2.70 -1.60 -2.22 -0.57 26 25 25 25
Enterprise Value (EV)		 158 125 288 404 316 321 610 392 284 556 377
Market Capitalization		 183 148 309 424 329 334 619 389 270 535 372
Book Value per Share		 $1.28 $1.17 $1.05 $0.92 $0.72 $0.71 $0.56 $0.99 $0.64 $0.36 $0.89
Tangible Book Value per Share		 $1.25 $1.14 $1.03 $0.90 $0.71 $0.71 $0.56 $0.23 ($0.07) ($0.32) $0.24
Total Capital		 45 42 29 25 20 49 45 77 68 61 78
Total Debt		 9.96 9.98 0.00 0.00 0.00 29 29 49 50 50 51
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 29 29 49 50 50 51
Net Debt		 -25 -23 -22 -20 -12 -13 -9.02 3.15 14 21 4.66
Capital Expenditures (CapEx)		 0.00 0.00 0.01 0.26 0.18 0.09 0.20 0.05 0.65 0.21 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 7.02 7.00 5.20 2.91 4.96 5.05 5.06 6.91 9.80 9.26 11
Debt-free Net Working Capital (DFNWC)		 42 40 27 23 17 47 43 53 45 39 57
Net Working Capital (NWC)		 32 30 27 23 17 47 43 53 45 39 57
Net Nonoperating Expense (NNE)		 1.18 1.09 1.35 1.46 1.71 1.86 2.20 2.85 3.62 4.17 3.03
Net Nonoperating Obligations (NNO)		 -25 -23 -22 -20 -12 -13 -9.02 3.15 14 21 4.66
Total Depreciation and Amortization (D&A)		 0.49 0.48 0.52 0.47 0.33 0.65 0.47 0.87 1.16 1.43 1.68
Debt-free, Cash-free Net Working Capital to Revenue		 26.85% 24.92% 17.10% 9.26% 15.39% 15.04% 14.72% 18.70% 24.14% 21.89% 23.43%
Debt-free Net Working Capital to Revenue		 161.99% 141.94% 88.00% 73.30% 53.82% 138.70% 126.05% 142.91% 111.78% 91.34% 124.95%
Net Working Capital to Revenue		 123.90% 106.39% 88.00% 73.30% 53.82% 138.70% 126.05% 142.91% 111.78% 91.34% 124.95%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.16) ($0.16) ($0.18) ($0.20) ($0.22) ($0.21) ($0.21) ($0.26) ($0.32) ($0.38) ($0.24)
Adjusted Weighted Average Basic Shares Outstanding		 25.45M 27.47M 27.59M 27.03M 27.72M 28.26M 28.43M 28.32M 29.55M 30.17M 30.98M
Adjusted Diluted Earnings per Share		 ($0.16) ($0.16) ($0.18) ($0.20) ($0.22) ($0.21) ($0.21) ($0.26) ($0.32) ($0.38) ($0.24)
Adjusted Weighted Average Diluted Shares Outstanding		 25.45M 27.47M 27.59M 27.03M 27.72M 28.26M 28.43M 28.32M 29.55M 30.17M 30.98M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.42M 27.60M 27.58M 27.63M 27.99M 28.43M 28.42M 29.66M 29.99M 30.50M 32.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.96 -3.32 -3.62 -3.92 -4.31 -3.98 -3.69 -4.93 -5.93 -7.17 -4.43
Normalized NOPAT Margin		 -38.77% -42.22% -44.58% -50.48% -50.84% -43.15% -41.68% -47.37% -48.93% -65.91% -36.71%
Pre Tax Income Margin		 -54.27% -56.10% -61.24% -69.31% -70.81% -63.07% -66.39% -74.76% -78.69% -104.55% -61.81%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -71.65 -9.83 -3.69 -6.16 -7.25 -4.36
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -49.70 -6.80 -2.57 -4.29 -5.07 -3.07
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -72.79 -10.20 -3.72 -6.63 -7.41 -4.46
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -50.84 -7.17 -2.60 -4.76 -5.23 -3.16
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ClearPoint Neuro’s financial statements show strong long-term revenue growth, but the company remains deeply unprofitable and increasingly dependent on debt and equity financing. The latest figures cover the quarter ended June 30, 2026, with historical comparisons extending back to 2022.

  • Revenue has expanded substantially over the long term. Quarterly revenue increased from $5.1 million in Q3 2022 to $10.9 million in Q2 2026, although Q2 2026 revenue declined 10.3% from $12.1 million in Q1 2026.
  • Gross profit and gross margin remain meaningful. Q2 2026 gross profit was $6.7 million, representing a gross margin of approximately 61.7%. The margin remains well above the roughly 52.5% reported in Q2 2023, despite declining from approximately 64.0% in Q1 2026.
  • Liquidity is still supported by a sizable current-asset base. ClearPoint Neuro held $48.9 million of current assets and $10.3 million of current liabilities at June 30, 2026, implying a current ratio of roughly 4.7. Cash and equivalents totaled $29.4 million.
  • Quarterly cash burn improved sequentially. Net cash used in operating activities decreased from $8.0 million in Q1 2026 to $7.0 million in Q2. The company also received $1.0 million from financing activities during Q2, partially offsetting its operating cash requirements.
  • Accounts receivable and inventory require monitoring. Accounts receivable was $8.4 million and inventory was $8.8 million at the end of Q2 2026. Receivables declined slightly from Q1, while inventory increased, potentially tying up additional working capital.
  • Noncash expenses materially reduce the gap between net loss and operating cash flow. Q2 2026 included $1.3 million of amortization, $2.8 million of other noncash adjustments and $150,000 of depreciation. Investors should recognize that these adjustments do not eliminate the company’s underlying cash consumption.
  • Losses have widened sharply. Q2 2026 net loss was $11.3 million, or $0.38 per share, compared with a $9.6 million loss in Q1 2026, a $7.8 million loss in Q4 2025 and a $5.9 million loss in Q3 2025. ClearPoint Neuro has remained loss-making throughout the supplied period.
  • Operating expenses continue to exceed gross profit by a wide margin. Q2 2026 operating expenses totaled $17.0 million, including $6.8 million of marketing expense, $5.6 million of selling, general and administrative expense and $4.6 million of research and development expense. Operating expenses rose from $13.4 million in Q4 2025 despite the company’s revenue growth.
  • Debt has increased considerably. Long-term debt rose from zero in early 2024 to $28.8 million in Q2 2025 and $50.2 million in Q2 2026. Interest expense was $1.4 million in Q2 2026, and cash interest paid was $536,000, adding pressure to the company’s already negative earnings and cash flow.
  • Shareholder dilution and declining equity are important risks. Weighted-average basic shares increased from 25.5 million in Q1 2024 to 30.2 million in Q2 2026. Meanwhile, total equity declined from $19.7 million in Q2 2025 to $10.8 million in Q2 2026 as accumulated losses grew. Continued cash burn could require additional borrowing or equity issuance.

Overall, ClearPoint Neuro’s revenue trajectory and gross margins are encouraging, but those gains have not yet translated into operating leverage or positive cash flow. The central issues for investors are whether revenue can resume its upward trend, whether marketing and research spending can generate sufficient growth, and how long the company can fund losses while carrying approximately $50 million of long-term debt.

11/14/26 08:00 PM ETAI Generated. May Contain Errors.

ClearPoint Neuro Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ClearPoint Neuro's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

ClearPoint Neuro's net income appears to be on a downward trend, with a most recent value of -$25.54 million in 2025, falling from -$8.45 million in 2015. The previous period was -$18.91 million in 2024. Find out what analysts predict for ClearPoint Neuro in the coming months.

ClearPoint Neuro's total operating income in 2025 was -$24.16 million, based on the following breakdown:
  • Total Gross Profit: $22.69 million
  • Total Operating Expenses: $46.86 million

Over the last 10 years, ClearPoint Neuro's total revenue changed from $4.59 million in 2015 to $36.97 million in 2025, a change of 704.7%.

In the past 13 quarters, ClearPoint Neuro's cash and equivalents has ranged from $12.39 million in Q1 2025 to $46.18 million in Q3 2026, and is currently $46.18 million as of their latest financial filing in Q3 2026.

ClearPoint Neuro had total debt of $49.08 million at the end of 2025, compared with none in 2024, and a 1,061.7% increase since 2015.

Over the last 10 years, ClearPoint Neuro's book value per share changed from -0.03 in 2015 to 0.99 in 2025.


Related Companies

Financial statements for NASDAQ:CLPT last updated on 10/28/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The Democrats can’t stop this
Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...
Porter & Company | Sponsoredtc pixel
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...
Weiss Ratings | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Elon wants to move AI off the planet. Amazon isn't ready.
What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...
StocksToTrade | Sponsoredtc pixel
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...
Monument Traders Alliance | Sponsoredtc pixel